Keros Therapeutics Posts Wider Q2 Loss of $1.45/Share
KROS is trading near its 52-week low of $9.69 (4.3% above the low).
Summary
Keros Therapeutics reported a Q2 loss of $1.45 per share, widening from the $1.21 loss in Q1. The stock is trading near its 52-week low of $9.69, and the deeper loss adds pressure. The company recently earned a $20M milestone from Takeda for the Phase 3 ELRi trial start, but cash burn remains a concern. Keros expects its cash and cash equivalents to fund operating expenses and capital expenditures into the first half of 2028. The CFO resignation effective today adds to the uncertainty.
At the time of this announcement, KROS was trading at $10.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.1M. The 52-week trading range was $9.69 to $22.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.